Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

British Journal of Cancer

Volumn 106, Issue 11, 2012, Pages 1798-1806

  Ali, H R ^a,b,c   Dawson, S J ^a,b,c   Blows, F M ^d   Provenzano, E ^b,c,e   Pharoah, P D ^a,d,e   Caldas, C ^a,b,c,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Cambridge Experimental Cancer Medicine Centre ECMC   (United Kingdom)

Author keywords

aurora kinase A; ER positive; geminin; Ki67; MCM2; prognosis

Indexed keywords

AURORA A KINASE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMININ; HISTONE H3; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; POLO LIKE KINASE 1; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL CYCLE; CELL PROLIFERATION; DISEASE MARKER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84861457376     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.167     Document Type: Article

References (53)

1. Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, Reis-Filho JS, Ellis IO (2010) Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 222(4): 388-399
2. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127(3): 591-599
3. Ali AM, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, Huntsman D, Caldas C, Pharoah PD (2011) Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer 104(4): 693-699
4. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C (2012) A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 226(1): 97-107
5. Azzato E, Greenberg D, Shah M, Blows F, Driver K, Caporaso N, Pharoah P (2009) Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 100(11): 1806-1811
6. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14): 1658-1667
7. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17): 1784-1792 (Pubitemid 41549890)
8. Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J, Cheang M, Gelmon K, Nielsen T, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen L, Bégin L, Foulkes W, Couch F, Wang X, Cafourek V, Olson J, Baglietto L, Giles G, Severi G, McLean C, Southey M, Rakha E, Green A, Ellis I, Sherman M, Lissowska J, Anderson W, Cox A, Cross S, Reed M, Provenzano E, Dawson S, Dunning A, Humphreys M, Easton D, García-Closas M, Caldas C, Pharoah P, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7(5): e1000279
9. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, Pharoah PD, Caldas C (2003) Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12(1): 27-34 (Pubitemid 36255267)
10. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8(11): 1323-1327 (Pubitemid 35373567)
11. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10): 736-750
12. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS (2011) Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 13(3): 212
13. Colozza M, Sidoni A, Piccart-Gebhart M (2010) Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11(5): 414-415
14. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16): 5158-5165
15. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22): 1656-1664
16. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH (2005) Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11(7): 2510-2517 (Pubitemid 40569447)
17. EBCTCG (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352(9132): 930-942
18. Endl E, Kausch I, Baack M, Knippers R, Gerdes J, Scholzen T (2001) The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells. J Pathol 195(4): 457-462 (Pubitemid 33069671)
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Members P (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8): 1736-1747
20. Gonzalez M, Tachibana K, Chin S, Callagy G, Madine M, Vowler S, Pinder S, Laskey R, Coleman N (2004) Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204(2): 121-130 (Pubitemid 39335284)
21. Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, Bell JA, Laskey RA, Coleman N (2003) Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21(23): 4306-4313 (Pubitemid 46628462)
22. Gonzalez MA, Tachibana KE, Laskey RA, Coleman N (2005) Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 5(2): 135-141 (Pubitemid 40215861)
23. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104(4): 311-325
24. Henderson IC (2010) Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat 123(1): 159-162
25. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA (2002) Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 12(1): 1-6 (Pubitemid 34003065)
26. Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4(12): 927-936 (Pubitemid 39626216)
27. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20): 1566-1575 (Pubitemid 35315837)
28. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M, Sauter G, Kallioniemi O (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847 (Pubitemid 28331029)
29. Kulkarni AA, Loddo M, Leo E, Rashid M, Eward KL, Fanshawe TR, Butcher J, Frost A, Ledermann JA, Williams GH, Stoeber K (2007) DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res 13(20): 6153-6161 (Pubitemid 350075075)
30. Lens SM, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10(12): 825-841
31. Lesueur F, Pharoah P, Laing S, Ahmed S, Jordan C, Smith P, Luben R, Wareham N, Easton D, Dunning A, Ponder B (2005) Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 14(16): 2349-2356 (Pubitemid 41417997)
32. Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, El-Sheikh S, Falzon M, Eward KL, Prevost T, Sainsbury R, Stoeber K, Williams GH (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100(6): 959-970
33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Diagnostics SSotN-EWGoC (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16): 1180-1184 (Pubitemid 41258223)
34. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty TD (2001) Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 7(9): 2712-2718 (Pubitemid 32911375)
35. Moons KGM, RART Donders, Stijnen T, Harrell JFE (2006) Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 59(10): 1092-1101 (Pubitemid 44389818)
36. Nadler Y, Camp R, Schwartz C, Rimm D, Kluger H, Kluger Y (2008) Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 14(14): 4455-4462
37. Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12(6): 631-635
38. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27): 2817-2826 (Pubitemid 40051905)
39. Perou C, Sørlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, Fluge O, Pergamenschikov A, Williams C, Zhu S, Lønning P, Børresen-Dale A, Brown P, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797): 747-752
40. Pharoah PD, Caldas C (2010) Genetics: how to validate a breast cancer prognostic signature. Nat Rev Clin Oncol 7(11): 615-616
41. Pritchard KI (2011) Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy? Breast Cancer Res Treat 127(2): 587-588
42. Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, Hyland A, Todorov IT, Brooks JS, Bepler G (2001) MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19(22): 4259-4266 (Pubitemid 33081644)
43. Regierer AC, Wolters R, Kurzeder C, Wöckel A, Novopashenny I, Possinger K, Wischnewsky MB, Kreienberg R (2011) High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS? Breast Cancer Res Treat 128(1): 273-281
44. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118(9): 2190-2194
45. Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH, Stoeber K (2005) DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer 93(11): 1295-1300 (Pubitemid 41679416)
46. Sørlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Eystein Lønning P, Børresen-Dale A (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19): 10869-10874
47. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. The Breast 17(4): 323-334
48. Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO, Aparicio S, Brenton JD, Caldas C (2006) A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 7(10): R101
49. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212-7220
50. Williams GH, Stoeber K (2007) Cell cycle markers in clinical oncology. Curr Opin Cell Biol 19(6): 672-679 (Pubitemid 350216427)
51. Williams GH, Stoeber K (2012) The cell cycle and cancer. J Pathol 226(2): 352-364
52. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4): R65
53. Yerushalmi R, Woods R, Ravdin P, Hayes M, Gelmon K (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2): 174-183